Literature DB >> 25740667

Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?

S Mohapatra1, A Saxena, G Gandhi, B C Koner, T Singh, P C Ray.   

Abstract

OBJECTIVE: Vitamin D deficiency is reported to be involved in pathogenesis of ovarian cancer. But the mechanism is yet to be explored. An imbalance between Th1 and Th2 activity play a crucial role in pathogenesis of many cancers. The purpose of the study is to find out the Th1/Th2 status by estimating TNF-α (Th1 marker) and IL-4 (Th2 marker) in ovarian cancer cases and controls and to correlate these with serum vitamin D levels.
MATERIALS AND METHODS: A case-control study with 50 ovarian cancer cases and 50 healthy controls was conducted. The cytokines TNF-α and IL-4 were estimated by ELISA. Serum vitamin D was measured by electro-chemiluminescence immunoassay method.
RESULTS: Median TNF-α levels (12.2 vs 6.2 pg/ml; p value <0.001) were significantly higher in ovarian cancer patients and mean IL-4 levels (2.22 ± 0.51 vs 2.99 ± 0.68 pg/ml; p value <0.05) were significantly lower as compared to those of controls. Levels of TNF-α and IL-4 did not vary significantly with clinical staging, and histological grading. Vitamin D levels were negatively correlated with TNF-α and positively correlated with IL-4.
CONCLUSIONS: Low vitamin D levels promotes Th1 activity increasing TNF-α levels and inhibits Th2 activity decreasing IL-4 levels in ovarian cancer. These low levels of vitamin D may induce pro-inflammatory micro ambience which might contribute to pathogenesis of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740667     DOI: 10.1007/s12094-015-1281-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Interleukin-4 mediates cell growth inhibition through activation of Stat1.

Authors:  T L Chang; X Peng; X Y Fu
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

3.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

Authors:  Srinivasan Madhusudan; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Trivadi S Ganesan
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

Review 4.  Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system.

Authors:  Margherita T Cantorna; Yan Zhu; Monica Froicu; Anja Wittke
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

5.  Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.

Authors:  Kathy J Helzlsouer
Journal:  Am J Epidemiol       Date:  2010-06-18       Impact factor: 4.897

6.  Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies.

Authors:  M S Topp; C A Papadimitriou; F Eitelbach; M Koenigsmann; E Oelmann; B Koehler; D Oberberg; B Reufi; H Stein; E Thiel
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

7.  Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.

Authors:  Peter W Szlosarek; Matthew J Grimshaw; Hagen Kulbe; Julia L Wilson; George D Wilbanks; Frances Burke; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

8.  Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study.

Authors:  Mazda Jenab; H Bas Bueno-de-Mesquita; Pietro Ferrari; Franzel J B van Duijnhoven; Teresa Norat; Tobias Pischon; Eugène H J M Jansen; Nadia Slimani; Graham Byrnes; Sabina Rinaldi; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sophie Morois; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Manuela M Bergmann; Antonia Trichopoulou; Gesthimani Misirli; Dimitrios Trichopoulos; Franco Berrino; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Martine M Ros; Carla H van Gils; Petra H Peeters; Magritt Brustad; Eiliv Lund; María-José Tormo; Eva Ardanaz; Laudina Rodríguez; Maria-José Sánchez; Miren Dorronsoro; Carlos A Gonzalez; Göran Hallmans; Richard Palmqvist; Andrew Roddam; Timothy J Key; Kay-Tee Khaw; Philippe Autier; Pierre Hainaut; Elio Riboli
Journal:  BMJ       Date:  2010-01-21

9.  Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer.

Authors:  Robert Goldstein; Charles Hanley; Jonathan Morris; Declan Cahill; Ashish Chandra; Peter Harper; Simon Chowdhury; John Maher; Sophie Burbridge
Journal:  Cancers (Basel)       Date:  2011-12-16       Impact factor: 6.639

Review 10.  Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Francesca Sperati; Patrizia Vici; Marcello Maugeri-Saccà; Saverio Stranges; Nancy Santesso; Luciano Mariani; Antonio Giordano; Domenico Sergi; Laura Pizzuti; Luigi Di Lauro; Maurizio Montella; Anna Crispo; Marcella Mottolese; Maddalena Barba
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

View more
  3 in total

Review 1.  Vitamin D in prostate cancer.

Authors:  Donald L Trump; Jeanny B Aragon-Ching
Journal:  Asian J Androl       Date:  2018 May-Jun       Impact factor: 3.285

2.  Protective effects of vitamin D3 on fimbrial cells exposed to catalytic iron damage.

Authors:  Francesca Uberti; Vera Morsanuto; Debora Lattuada; Barbara Colciaghi; Andrea Cochis; Alessandro Bulfoni; Paola Colombo; Giorgio Bolis; Claudio Molinari
Journal:  J Ovarian Res       Date:  2016-06-17       Impact factor: 4.234

3.  Calcitriol and cancer therapy: A missed opportunity.

Authors:  Donald L Trump
Journal:  Bone Rep       Date:  2018-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.